Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for Q4 2024, reaching USD 7.6 billion, driven by strong performance in HIV, oncology, and liver disease segments. Full-year revenues also rose 6% to USD 28.8 billion.
Product Performance
- HIV Products: Q4 sales reached USD 5.5 billion (+16%), with full-year revenues at USD 19.6 billion (+8%). Biktarvy led the segment with Q4 sales of USD 3.8 billion (+21%) and full-year sales of USD 13.4 billion (+13%).
- Liver Disease: Q4 revenues increased 4% to USD 719 million, with full-year revenues up 9% to USD 3 billion.
- Cell Therapy: Q4 revenues from Yescarta and Tecartus rose 5% to USD 488 million, and full-year revenues increased 6% to USD 2 billion.
- ADC Trodelvy: Delivered robust growth, with Q4 sales of USD 355 million (+19%) and full-year sales of USD 1.3 billion (+24%).
Geographical Breakdown
- US Market: Q4 revenues at USD 5.55 billion, with full-year revenues of USD 20.508 billion.
- Europe: Q4 revenues at USD 1.16 billion, with full-year revenues of USD 4.576 billion.
- Other Markets: Q4 revenues at USD 826 million, with full-year revenues of USD 3.526 billion.
Outlook for 2025
Gilead plans to commercialize new products, including long-acting HIV therapy lenacapavir and seladelpar for primary biliary cirrhosis (PBC). The company expects 2025 product sales between USD 28.2 billion and USD 28.6 billion, or USD 26.7 billion to USD 27.2 billion excluding Veklury.-Fineline Info & Tech
